As the world crosses the 1-year mark since the World Health Organization classified COVID-19 as a pandemic, testing is still as crucial as ever. The United States tests an average of 2.78 people per...
The Partnership Back in May 2019, Biomeme and INDICAL Bioscience entered into an exclusive global licensing and research agreement in a joint effort to improve animal health globally. At the time,...
Table of Contents: What is a variant? Why are we just now hearing about variants of SARS-CoV-2? What are the current emerging SARS-CoV-2 variants to know? Should we be worried about these SARS-CoV-2...
We are thrilled to announce Biomeme, Inc. has been awarded a Redevelopment Assistance Capital Program (RACP) grant of $3 million from the Commonwealth of Pennsylvania. This RACP Grant will enable our...
List of SARS-CoV-2 Variants & Classifications Biomeme continuously monitors and analyzes sequences of emerging variants of concern and updates this table accordingly. Variant CDC Label CDC Variant...
The finalists have been announced and Biomeme is moving forward to the next round of XPRIZE Rapid COVID Testing, a $6 million dollar 6-month competition to create increased and more accessible...
When you walk into Biomeme HQ in Philadelphia, you’ll find a bustling office overflowing with our staff, incoming and outgoing packages, and an overworked coffee machine (our office appliances might...
Launched on July 28, 2020, XPRIZE Rapid Covid Testing is a $5 million, 6-month competition that aims to increase Covid-19 testing capabilities 100-times past our current standard, the level of...
We all want to make the world a better place, right? Whether you’re a doctor, public servant, or construction worker, we all play a part in making the world go round. All jobs are valuable, but some...
We are pleased to announce that the U.S. Food and Drug Administration (FDA) granted Biomeme’s SARS-CoV-2 Real-Time RT-PCR Test Emergency Use Authorization (EUA) for use in laboratories that meet...
